DEA Enforcement Update: Purdue Pharma, Red Flags, and Possible New Requirements for Handling Suspicious Orders

Recent U.S. Drug Enforcement Administration (DEA) enforcement activity continues to focus on the ongoing effects of the nation’s opioid addiction crisis. Enforcement actions by the Department of Justice on behalf of the DEA as well as the agency’s administrative registration revocation proceedings reflect the vigor of the government’s enforcement work and reveal its continuing focus on investigating alleged wrongdoing by both business organizations and individuals dealing with controlled substances.

This white paper, brought to you by the experts at Thompson Controlled Substances, tracks the latest DEA enforcement trends, analyzes important recent cases and settlements, and outlines an important proposed agency rule on how to handle suspicious controlled substance orders.